Effect of Roux-en-Y Gastric Bypass on Lipoprotein Metabolism and Markers of HDL Functionality in Morbid Obese Patients.
Atherosclerosis
Bariatric surgery
HDL
Obesity
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
30
06
2020
accepted:
21
10
2020
revised:
15
10
2020
pubmed:
1
11
2020
medline:
20
4
2021
entrez:
31
10
2020
Statut:
ppublish
Résumé
Morbid obesity represents the most severe form of obesity and surgical intervention would be its only successful treatment. Bariatric surgery could generate modifications in carbohydrate metabolism and in lipid profile plus lipoprotein-associated proteins and enzymes, such as lipoprotein-associated phoslipase A Thirty-seven patients with morbid obesity were recruited. Evaluations were performed before (T0) and 1 (T1) and 6 (T2) months after surgery. Glucose, insulin, high-sensitivity C-reactive protein (hsCRP), triglycerides, total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, apolipoproteins (apo) A-I, and B plus Interleukin 1β and 6 levels in addition to CETP, Lp-PLA2, and PON 1 activities were determined. Body mass index decreased at T1 and T2 (p < 0.01). An improvement in all markers of insulin resistance (p < 0.05) was observed at T1. hsCRP levels diminished at T2 (p < 0.05). Triglyceride levels decreased at T1 and T2 (p < 0.05). HDL-C and apo A-I showed a decrease at T1 which was completely reversed at T2 (p < 0.05). Lp-PLA These results would be indicative of a favorable effect of bariatric surgery on markers of carbohydrate metabolism and cardiovascular disease lipid risk factors.
Identifiants
pubmed: 33128217
doi: 10.1007/s11695-020-05076-0
pii: 10.1007/s11695-020-05076-0
doi:
Substances chimiques
Cholesterol Ester Transfer Proteins
0
Cholesterol, HDL
0
Cholesterol, LDL
0
Lipoproteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1092-1098Références
Moore D. The developing genome: an introduction to behavioral epigenetics. 1st ed: Oxford University Press; 2015.
Arteaga A. Overweight and obesity as a universal health problem. Rev Med Clin Condes. 2012;23:145–53.
Galic S, Oakhill J, Steinberg G. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316:129–39.
pubmed: 19723556
Michaud A, Boulet M, Veilleux A, et al. Abdominal subcutaneous and omental adipocyte morphology and its relation to gene expression, lipolysis and adipocytokine levels in women. Metabolism. 2013;63:372–81.
pubmed: 24369916
Wellen K, Hotamisligil G. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003;112:1785–8.
pubmed: 14679172
pmcid: 297006
Morisset A, Huot C, Légaré D, et al. Circulating IL-6 concentrations and abdominal adipocyte isoproterenol-stimulated lipolysis in women. Obesity (Silver Spring). 2008;16:1487–92.
Patel L, Buckels A, Kinghorn I, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun. 2003;300:472–6.
pubmed: 12504108
Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–50.
pubmed: 19302047
Paik J, Kim M, Kim M, et al. Circulating Lp-PLA2 activity correlates with oxidative stress and cytokines in overweight/obese postmenopausal women not using hormone replacement therapy. AGE. 2015;37:32–42.
pubmed: 25840804
pmcid: 4385327
da Silva IT, de Souza Timm A, Damasceno N. Influence of obesity and cardiometabolic makers on lipoprotein associated phospholipase A2 (Lp-PLA2) activity in adolescents: the healthy young cross-sectional study. Lipids Health Dis. 2013;12:19–27.
pubmed: 23413990
pmcid: 3605356
Onat A, Hergenç G. Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metab Clin Exp. 2011;60:499–512.
pubmed: 20580781
Onat A, Can G, Yüksel H. Dysfunction of high-density lipoprotein and its apolipoproteins: new mechanisms underlying cardiometabolic risk in the population at large. Turk Kardiyol Dern Ars. 2012;40:368–85.
pubmed: 22951857
Murphy A, Woollard K, Hoang A, et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol. 2008;28:2071–7.
pubmed: 18617650
Murphy A, Woollard K. High-density lipoprotein: a potent inhibitor of inflammation. Clin Exp Pharmacol Physiol. 2010;37:710–8.
pubmed: 19930423
Movva R, Rader D. Laboratory assessment of HDL heterogeneity and function. Clin Chem. 2008;54:788–800.
pubmed: 18375481
Rye K, Barter P. Formation and metabolism of pre beta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol. 2004;24:421–8.
pubmed: 14592845
Davidson W, Silva R, Chantepie S, et al. Proteomic análisis of defined HDL subpopulations reveals article specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol. 2009;29:870–6.
pubmed: 19325143
pmcid: 2845307
Kontush A, Therond P, Zerrad A, et al. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol. 2007;27:1843–9.
pubmed: 17569880
Chapman M, Le Goff W, Guerin M, et al. Cholesteryl ester transfer protein: at the heart of the action of lipid modulating therapy with statins, fibrates, niacin, and cholesteryl-ester transfer protein inhibitors. Eur Heart J. 2010;31:149–64.
pubmed: 19825813
Arai T, Yamashita S, Hirano K, et al. Increased plasma cholesteryl-ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler Thromb. 1994;14:1129–36.
pubmed: 8018669
Ebenbichler C, Laimer M, Kaser S, et al. Relationship between cholesterylester transfer protein and atherogenic lipoprotein profile in morbidly obese women. Arterioscler Thromb Vasc Biol. 2002;22:1465–9.
pubmed: 12231567
Aviram M, Rosenblat M, Bisgaier C, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role forparaoxonase. J Clin Invest. 1998;101:1581–90.
pubmed: 9541487
pmcid: 508738
Bajnok L, Csongradi E, Seres I, et al. Relationship of adiponectin to serum paraoxonase 1. Atherosclerosis. 2008;197:363–7.
pubmed: 17624354
Abell T, Minocha A. Gastrointestinal complications of bariatric surgery: diagnosis and therapy. Am J Med Sci. 2006;331:214–8.
pubmed: 16617237
Arterburn D, Courcoulas A. Bariatric surgery for obesity and metabolic conditions in adults. BMJ. 2014;349:g3961.
pubmed: 25164369
pmcid: 4707708
Nguyen N, DeMaria E, Ikramuddin S, et al. The SAGES manual: a practical guide to bariatric surgery. New York: Springer; 2008.
Blank M, Hall M, Cress E, et al. Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: higher activities in hypertensive rats. Biochem Biophys Res Commun. 1983;113:666–71.
pubmed: 6870880
Lowry O, Rosebrough N, Farr A, et al. Protein measurement with the folinphenol reagent. J Biol Chem. 1951;193:265–75.
pubmed: 14907713
Furlong C, Richter R, Seidel S, et al. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal Biochem. 1989;80:242–7.
Han TS, Lean ME. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovasc Dis. 2016;5:2048004016633371.
pubmed: 26998259
pmcid: 4780070
Yan Y, Sha Y, Yao G, et al. Roux-en-Y gastric bypass versus medical treatment for type 2 diabetes mellitus in obese patients: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95:e3462.
Vest AR, Heneghan HM, Agarwal S, et al. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart. 2012;98:1763–77.
pubmed: 23077152
Poirier P, Cornier MA, Mazzone T, et al. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation. 2011;123:1683–701.
pubmed: 21403092
Courcoulas AP, Christian NJ, Belle SH, et al. Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA. 2013;310:2416–25.
pubmed: 24189773
pmcid: 3955952
Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012;308:1122–31.
pubmed: 22990271
pmcid: 3744888
Asztalos BF, Swarbrick MM, Schaefer EJ, et al. Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women. J Lipid Res. 2010;51:2405–12.
pubmed: 20631298
pmcid: 2903819
Carlsson E, Allin K, Madsbad S, et al. Phosphatidylcholine and its relation to apolipoproteins A-1 and B changes after roux-en-Y gastric bypass: a cohort study. Lipids Health Dis. 2019;18:169.
pubmed: 31488158
pmcid: 6729082
Shih KC, Janckila AJ, Lee WJ, et al. Effects of bariatric weight loss surgery on glucose metabolism, inflammatory cytokines, and serum tartrate-resistant acid phosphatase 5a in obese Chinese adults. Clin Chim Acta. 2016;453:197–202.
pubmed: 26552040
Bray GA, Siri-Tarino PW. The role of macronutrient content in the diet for weight management. Endocrinol Metab Clin N Am. 2016;45:581–604.
Rolland C. Broom I the effects of very-low-calorie diets on HDL: a review. Cholesterol. 2011;306278:2011.
Shoji T, Nishizawa Y, Koyama H, et al. High-density-lipoprotein metabolism during a very-low-calorie diet. Am J Clin Nutr. 1992;56:297S–8S.
pubmed: 1615910
Desroches S, Paradis ME, Pérusse M, et al. A-II, and VLDL-B-100 metabolism in men: comparison of a low-fat diet and a high-monounsaturated fatty acid diet. J Lipid Res. 2004;45:2331–8.
pubmed: 15342678
Vélez-Carrasco W, Lichtenstein AH, Welty FK, et al. Dietary restriction of saturated fat and cholesterol decreases HDL ApoA-I secretion. Arterioscler Thromb Vasc Biol. 1999;19:918–24.
pubmed: 10195918
Gero D, Favre L, Allemann P, et al. Laparoscopic roux-en-Y gastric bypass improves lipid profile and decreases cardiovascular risk: a 5-year longitudinal cohort study of 1048 patients. Obes Surg. 2018;28:805–11.
pubmed: 28971303
De Stefano A, Mannucci L, Tamburi F, et al. Lp-PLA2, a new biomarkerof vascular disorders in metabolicdiseases. Int J Immunopathol Pharmacol. 2019;33:2058738419827154.
pubmed: 30706739
pmcid: 6360470
Julve J, Pardina E, Pérez-Cuéllar M, et al. Bariatric surgery in morbidly obese patients improves the atherogenic qualitative properties of the plasma lipoproteins. Atherosclerosis. 2014;234:200–5.
pubmed: 24674904
Oberbach A, von Bergen M, Blüher S, et al. Combined serum proteomic and metabolomics profiling after laparoscopic sleeve gastrectomy in children and adolescents. J Laparoendosc Adv Surg Tech A. 2012;22:184–8.
pubmed: 21958229
Ferretti G, Bacchetti T, Masciangelo S, et al. Altered inflammation, paraoxonase-1 activity and HDL physicochemical properties in obese humans with and without Prader-Willi syndrome. Dis Model Mech. 2012;5:698–705.
pubmed: 22822045
pmcid: 3424468
Van Gaal L, Zhang A, Steijaert M, et al. Human obesity: from lipid abnormalities to lipidoxidation. Int J Obes Relat Metab Disord. 1995;3:21–6.